Our approach allows us to engineer protein therapeutics with unparalleled precision, ensuring enhanced specificity, potency, and safety profiles.
Engineering expertise specialized in antibody biology for the development of novel monoclonal antibodies that are designed to target novel epitopes for optimized interaction with their target receptors.
Develop innovative cytokine-antibody fusion protein that can overcome the limitations of off-target toxicities in traditional cytokine therapies by merging the potent properties of cytokines with targeted antibody delivery.
Design therapeutic strategies that can effectively target the distinct receptors expressed on the surfaces of CD4+ and CD8+ T cells by leveraging our understanding of T cell biology.
